1 Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758–64.
2 Jarvis D, Luczynska C, Chinn S, et al. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. J Allergy Clin Immunol 2005;116:675–82.
3 Petersen KD, Kronborg C, Gyrd-Hansen D, et al. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy 2008;63:284–91.
4 Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseasesA WHO position paper. J Allergy Clin Immunol 1998;102:558–62.
5 varez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82): 1–20.
6 Bousquet J, Demoly P. Specific immunotherapy—an optimistic future. Allergy 2006;61:1155–8.
7 Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;4:CD001186.
8 Dam PK, Gyrd-Hansen D, Kjaergaard S, Dahl R. Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005;33:264–9.
9 Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005;33:296–302.
10 Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient’s perspective? BMC Pulm Med 2007;7:8.
11 Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med 2006;100:354–62.
12 Petersen KD, Gyrd-Hansen D, Linneberg A, et al. Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy. Int J Technol Assess Health Care 2010;26:20–9.
13 Linneberg A, Bodtger U. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population. Allergy 2007;62:825–6.
14 The Danish Medicines Agency. Statistik for lægemidler og lægemiddelgrupper. Available at: 
15 Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy 2005;60:1357–60.
16 Grossman M. On the concept of health capital and the demand for health. J Polit Econ 1972;80:223–55.
17 Mooney G. Economics, medicine and health care, 3rd edn. Dorchester, Dorset: Pearson Education Limited, 2003.
18 Folland S, Goodman AC, Stano M. The economics of health and health care, 4th edn. Oakland: Prentice Hall, 2004.
19 Viscusi WP, Moore MJ. Rates of time preference and valuations of the duration of life. J Public Econ 1989;38:297–317.
20 Bousquet J, van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147–S334.
21 Bachert C, van CP. The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. Chem Immunol Allergy 2003;82:119–26.
22 Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30(Suppl 1): 2–5.
23 Bousquet J, Clark TJ, Hurd S, et al. GINA guidelines on asthma and beyond. Allergy 2007;62:102–12.
24 EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199–208.
25 Pedersen KM, Wittrup-Jensen K, Brooks R, Guidex C. Værdisætning af sundhed. Teorien om kvalitetsjusterede levea  ̊r og en dansk anvendelse (Valuation of health. Theory of quality adjusted life years). Odense: University of Southern Denmark, (in Danish), 2006.
26 Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13–35.
27 Le CT, Boen JR. Health and number: basic biostatistical methods. New York: Wiley-Liss, Inc, 1995.
28 Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1997.